Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yuan Ji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2631-9082; OpenAlex author ID A5102011950. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 11

  1. Effect of tumor microenvironment in pancreatic cancer on the loss of β-cell mass: implications for type 3c diabetes. Co-author DOI 10.1007/s00535-024-02204-w↗
  2. Pancreatic Cancer-Targeting Cascade Nanoamplifier Enables Self-Replenishing H2O2 Generation and Autophagy Disruption in Chemodynamic Therapy. Co-author DOI 10.3390/pharmaceutics17091201↗
  3. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  4. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. Co-author DOI 10.1002/mco2.183↗
  5. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-022-01384-3↗
  6. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2019.02.010↗
  7. Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2019.01543↗
  8. [Factors influencing survival of patients with pancreatic adenocarcinoma after surgical resection]. Co-author DOI 10.3760/cma.j.issn.0376-2491.2018.08.011↗
  9. Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Co-author DOI 10.18632/oncotarget.10630↗
  10. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2013.1261↗
  11. Evaluation of pancreatic cancer by multiple breath-hold dynamic contrast-enhanced magnetic resonance imaging at 3.0T. Last author DOI 10.1016/j.ejrad.2012.05.011↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenchuan Wu · 4 shared papers, 2016–2025 · strength 0.62
  2. Wenhui Lou · 3 shared papers, 2013–2024 · strength 0.36
  3. Hui Li · 1 shared paper, 2025 · strength 0.28
  4. Jiaqi Yu · 1 shared paper, 2025 · strength 0.28
  5. Yee Lin Tang · 1 shared paper, 2025 · strength 0.28
  6. Xiaomu Li · 1 shared paper, 2025 · strength 0.26
  7. Ke Hu · 1 shared paper, 2025 · strength 0.26
  8. Na Zhang · 1 shared paper, 2025 · strength 0.26
  9. Xi Guo · 2 shared papers, 2019–2024 · strength 0.24
  10. Lili Wu · 2 shared papers, 2019–2024 · strength 0.24
  11. Dansong Wang · 2 shared papers, 2016–2024 · strength 0.22
  12. Dayong Jin · 2 shared papers, 2016–2024 · strength 0.22
  13. Wenhui Lou · 2 shared papers, 2016–2022 · strength 0.17
  14. Lie Yao · 1 shared paper, 2024 · strength 0.16
  15. Xuefeng Xu · 1 shared paper, 2024 · strength 0.16
  16. Yaolin Xu · 1 shared paper, 2024 · strength 0.16
  17. Yefei Rong · 1 shared paper, 2024 · strength 0.16
  18. Wenquan Wang · 1 shared paper, 2024 · strength 0.16
  19. Liang Liu · 1 shared paper, 2024 · strength 0.16
  20. Yuhong Zhou · 1 shared paper, 2024 · strength 0.16
  21. Tiantao Kuang · 1 shared paper, 2024 · strength 0.16
  22. Jing Liu · 1 shared paper, 2024 · strength 0.16
  23. Jun Zhang · 1 shared paper, 2024 · strength 0.16
  24. Deliang Fu · 1 shared paper, 2024 · strength 0.16
  25. Xiaowei Liu · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.